Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

Phase 3

Active, not recruiting

Conditions: RSV Infection

Interventions: Biological: Palivizumab
Biological: Clesrovimab
Biological: Placebo

First Posted Date: 2021-06-24

Last Posted Date: 2025-05-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1003

Registration Number: NCT04938830

Locations: 🇺🇸
DHR Health Institute for Research and Development ( Site 0029), Edinburg, Texas, United States
🇺🇸
NYU Langone Hospital - Long Island-Pediatrics ( Site 0028), Mineola, New York, United States
🇺🇸
Miller Children's & Women's Hospital Long Beach ( Site 0001), Long Beach, California, United States

and more 143 locations

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Phase 3

Active, not recruiting

Conditions: Metastatic Hormone-Sensitive Prostate Cancer

Interventions: Biological: Pembrolizumab
Drug: Enzalutamide
Drug: Androgen Deprivation Therapy (ADT)
Other: Placebo

First Posted Date: 2021-06-22

Last Posted Date: 2025-03-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 186

Registration Number: NCT04934722

Locations: 🇨🇳
Zhejiang Provincial People's Hospital ( Site 0809), Hangzhou, Zhejiang, China
🇨🇳
The First Affiliated Hospital of Wenzhou Medical University ( Site 0834), Wenzhou, Zhejiang, China
🇨🇳
The first affiliated Hospital of Xi an Jiaotong University ( Site # 0812), XI An, Shanxi, China

and more 21 locations

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Phase 2

Recruiting

Conditions: Pheochromocytoma/Paraganglioma
HIF-2α Mutated Cancers
Pancreatic Neuroendocrine Tumor
Von Hippel-Lindau Disease
Advanced Gastrointestinal Stromal Tumor

Interventions: Drug: Belzutifan

First Posted Date: 2021-06-11

Last Posted Date: 2025-05-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 322

Registration Number: NCT04924075

Locations: 🇺🇸
Cedars-Sinai Medical Center ( Site 0110), Los Angeles, California, United States
🇺🇸
Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130), Chicago, Illinois, United States
🇺🇸
University of Iowa ( Site 0104), Iowa City, Iowa, United States

and more 76 locations

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

Phase 2

Active, not recruiting

Conditions: Small Cell Lung Cancer

Interventions: Biological: Pembrolizumab
Drug: Lenvatinib
Biological: MK-4830
Biological: Boserolimab
Drug: Etoposide
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2021-06-11

Last Posted Date: 2025-05-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 120

Registration Number: NCT04924101

Locations: 🇺🇸
UPMC Hillman Cancer Center ( Site 0127), Pittsburgh, Pennsylvania, United States
🇺🇸
MFSMC-HJWCI-Oncology Research ( Site 0128), Baltimore, Maryland, United States
🇺🇸
Cleveland Clinic-Taussig Cancer Center ( Site 0116), Cleveland, Ohio, United States

and more 46 locations

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

Phase 1

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: MK-6194
Drug: MK-6194-matching placebo

First Posted Date: 2021-06-11

Last Posted Date: 2025-06-04

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 57

Registration Number: NCT04924114

Locations: 🇺🇸
IHS. Health, LLC ( Site 0104), Kissimmee, Florida, United States
🇺🇸
Pinnacle Clinical Research ( Site 0103), San Antonio, Texas, United States
🇩🇪
Charite Research Organisation GmbH ( Site 0201), Berlin, Germany

and more 14 locations

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

Phase 3

Completed

Conditions: Biliary Tract Carcinoma

Interventions: Biological: Pembrolizumab
Drug: Gemcitabine
Drug: Placebo
Drug: Cisplatin

First Posted Date: 2021-06-11

Last Posted Date: 2025-04-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 158

Registration Number: NCT04924062

Locations: 🇨🇳
Anhui Provincial Hospital ( Site 0140), Hefei, Anhui, China
🇨🇳
Beijing Cancer Hospital ( Site 0138), Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital ( Site 0150), Beijing, Beijing, China

and more 19 locations

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Phase 3

Terminated

Conditions: Prostatic Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Docetaxel
Drug: Placebo
Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2021-05-28

Last Posted Date: 2024-07-12

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 81

Registration Number: NCT04907227

Locations: 🇨🇳
The First Affiliated Hospital of Xiamen University ( Site 1319), Xiamen, Fujian, China
🇨🇳
Hunan Cancer Hospital ( Site 1320), Changsha, Hunan, China
🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine ( Site 1309), Hangzhou, Zhejiang, China

and more 17 locations

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Phase 3

Active, not recruiting

Conditions: Breast Neoplasms

Interventions: Biological: pembrolizumab
Drug: paclitaxel
Drug: nab-paclitaxel
Drug: liposomal doxorubicin
Drug: capecitabine
Drug: normal saline
Drug: dextrose

First Posted Date: 2021-05-20

Last Posted Date: 2025-03-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 340

Registration Number: NCT04895358

Locations: 🇺🇸
Parkview Research Center at Parkview Regional Medical Center ( Site 0071), Fort Wayne, Indiana, United States
🇺🇸
University of Illinois at Chicago ( Site 0061), Chicago, Illinois, United States
🇫🇷
Institut de Cancérologie de l'Ouest ( Site 0915), ANGERS cedex 02, Maine-et-Loire, France

and more 253 locations

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Biological: Pembrolizumab
Biological: Pembrolizumab/Quavonlimab
Biological: Pembrolizumab/Favezelimab
Biological: Pembrolizumab/Vibostolimab
Biological: MK-4830

First Posted Date: 2021-05-20

Last Posted Date: 2025-06-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 302

Registration Number: NCT04895722

Locations: 🇺🇸
University of Chicago Medical Center-Medicine - Section of Hematology/Oncology - Gastrointestinal P, Chicago, Illinois, United States
🇺🇸
UPMC Hillman Cancer Center ( Site 1516), Pittsburgh, Pennsylvania, United States
🇨🇦
The Moncton Hospital-Oncology ( Site 0307), Moncton, New Brunswick, Canada

and more 106 locations

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

Phase 3

Completed

Conditions: Malignant Melanoma

Interventions: Biological: Pembrolizumab
Drug: Placebo for lenvatinib
Drug: Lenvatinib

First Posted Date: 2021-05-17

Last Posted Date: 2024-12-02

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 131

Registration Number: NCT04889118

Locations: 🇨🇳
Nanjing Drum Tower Hospital (0609), Nanjing, Jiangsu, China
🇨🇳
Beijing Cancer Hospital (0601), Beijing, Beijing, China
🇨🇳
Sun Yat-Sen University Cancer Center (0602), Guangzhou, Guangdong, China

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy